Background: We report results of the first interim analysis (IA) from the ALTA-1L study of BRG vs CRZ in anaplastic lymphoma kinase (ALK) inhibitor–naive, ALK-positive non–small cell lung cancer (ALK+ NSCLC). Eligible pts had 1 or 2 brain metastases. At data cutoff (19 Feb 2018), with a median follow-up of 11.0/9.3 months, 275 pts were randomized (BRG/CRZ, n = 137/138); median age (years) 58/60. 26%/27% had baseline brain metastases. At data cutoff, with a median follow-up of 11.0/9.3 months, 106 O. Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

BRG (n = 137) CRZ (n = 138) P Value
All pts BIRC-Assessed Endpoint, %
Confirmed ORR 76 (68–83%) 73 (65–80%) 0.0678
With any intracranial CNS metastases
iORR 71 (62–78%) 60 (51–68%) 0.0678
With measurable intracranial CNS metastases
1-year IPFS 67 (47–80%) 67 (47–80%) 0.27 (0.13–0.54) <0.0001

Table 106O

Conclusions: BRG showed a statistically and clinically significant improvement in PFS vs CRZ in ALK inhibitor–naive ALK+ NSCLC.

Clinical trial identification: NCT02737501.

Editorial acknowledgement: Professional medical writing assistance was provided by Lauren Gallagher, PhD. (Peloton Advantage, Parsippany, NJ) and funded by Millennium Pharmaceuticals, Inc.

Legal entity responsible for the study: ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Funding: ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure: R. Califano: Honoraria, consulting/advisory role: AstraZeneca, BMS, Roche, MSD, Boehringer Ingelheim, Takeda, Novartis, Pfizer, Lilly Oncology. C. Gridelli: Speakers bureau, advisory role: Pfizer, Roche. A. Delmonte: Consulting/advisory role: AstraZeneca, Boehringer Ingelheim. M.R. Garcia Campelo: Honoraria: ARIAD, AstraZeneca, Roche, Pfizer, BMS, Boehringer Ingelheim; Speakers bureau, advisory role: ARIAD, AstraZeneca, Roche, Pfizer, BMS, Boehringer Ingelheim. A. Bearz: Speakers bureau, advisory role: AstraZeneca, Pfizer, Eli Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim. F. Griesinger: Research funding to institution: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Siemens; Consulting or advisory role: ARIAD, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, A. Morabito: Honoraria: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, ARIAD, Abbvie, Siemens. E. Felip: Consulting/advisory role: AbbVie, AstraZeneca, Blue Print Medicine, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Guardant Health, Janssen, Merck KGaA, MSD, Novartis, Pfizer, Roche, Takeda; Speakers bureau: AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Merck KGaA, MSD, Novartis, Pfizer, Roche, Takeda; S. Popat: Research funding to institution: Boehringer Ingelheim, Epizyme, BMS, Clovis Oncology, Roche, Lilly, Takeda; Honoraria: Boehringer Ingelheim, AstraZeneca, Roche, Takeda, Chugai Pharma; Consulting or advisory role: Boehringer Ingelheim, Roche, Novartis, Pfizer, AstraZeneca, BMS, MSD, Guardant Health, AbbVie; Travel, accommodations, expenses: Boehringer Ingelheim, BMS, Merck Sharp & Dohme. A. Morabito: Honoraria: AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, MSD. S. Ghosh: Honoraria/speakers bureau: Pfizer. M. Tiseo: Speakers bureau, advisory role: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Otaka, Pfizer, Pierre Fabre, Roche. J. Haney, D. Kerstein: Employment, stock and other ownership interests: Ariad. D.R. Camidge: Honoraria: AstraZeneca, Boehringer Ingelheim, Arri/Kyn, Genoptix, GI Therapeutics (DSMB), Mersana Therapeutics, Roche/Genentech, Ignyta, Daichii Sankyo (ILD adjudication committee). Hanosh SRC, Bio-Thera DSM, Lycera, Revolution Med, Orion, Clovis, Celgene, Novartis; Research funding (ARIAD/Takeda); All other authors have declared no conflicts of interest.